Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.63 |
| ▸ | ITK | Q08881 | 6/20 | 0.63 |
| ▸ | BTK | Q06187 | 8/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.59 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | LYN | P07948 | 1/20 | 0.57 |
| ▸ | TEC | P42680 | 1/20 | 0.57 |
| ▸ | TXK | P42681 | 1/20 | 0.57 |
| ▸ | BMX | P51813 | 1/20 | 0.57 |
| ▸ | CD69 | Q07108 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16391064 | 1.00 | EGFR (0.63) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL16697962 | 1.00 | EGFR (0.63) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL21338074 | 0.92 | EGFR (0.52) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL16391063 | 0.90 | EGFR (0.67) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL16698236 | 0.90 | EGFR (0.67) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL16391058 | 0.90 | EGFR (0.67) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL16391055 | 0.88 | EGFR (0.65) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL16371328 | 0.88 | EGFR (0.65) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL16371329 | 0.88 | EGFR (0.65) | EGFRITKBTKJAK3ERBB2 | |
| SCHEMBL16391083 | 0.86 | EGFR (0.78) | EGFRITKBTKJAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486865-A | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112592334-B | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-112592334-A | Pyrimidine derivatives as kinase inhibitors | 艾森生物科学公司 | 2021-04-02 | — | — | CN | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| WO-2015006754-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | EGFR 16/4885ITK 4/4885BTK 3/4885 |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | EGFR 16/4885ITK 4/4885BTK 3/4885 |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | BMX, BLK, BTK | EGFR 16/4885ITK 4/4885BTK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.